Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome

References

• Asherson RA, Cervera R. Unusual manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol 2003; 25: 61–78
   PubMed Web of Science ®Google Scholar
• Katzav A, Chapman J, Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 2003; 12: 903–907
   PubMedGoogle Scholar
• Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003; 42: 200–213
   PubMed Web of Science ®Google Scholar
• Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Mathieu A, Hughes GR. Neuropsychiatric manifestations in systemic lupus erythematosus: Prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985–992
   PubMed Web of Science ®Google Scholar
• Shavit YB, Graus F, Probst A, Rene R, Steck AJ. Epilepsia partialis continua: A new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999; 45: 255–258
   PubMedGoogle Scholar
• Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Arch Neurol 2002; 59: 195–201
   PubMed Web of Science ®Google Scholar
• Chapman AG. Glutamate receptors in epilepsy. Prog Brain Res 1998; 116: 371–383
   PubMed Web of Science ®Google Scholar
• Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994; 44: S14–S23
   PubMed Web of Science ®Google Scholar
• Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, Hughes TE, Heinemann SF, McNamara JO. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265: 648–651
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Bernasconi P, Baggi F, Spreafico R, Ragona F, Antozzi C, Bernardi G, Granata T. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002; 131: 179–185
   PubMedGoogle Scholar
• Wiendl H, Bien CG, Bernasconi P, Fleckenstein B, Elger CE, Dichgans J, Mantegazza R, Melms A. GluR3 antibodies: Prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001; 57: 1511–1514
   PubMed Web of Science ®Google Scholar
• Ganor Y, Goldberg-Stern H, Amrom D, Lerman-Sagie T, Teichberg VI, Pelled D, Futerman AH, Ben-Zeev B, Freilinger M, Verheulpen D, Van Bogaert P, Levite M. Autoimmune epilepsy: Some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood–brain barrier, which may kill neurons and decrease in brain fluids after Hemispherotomy. Clin Dev Immunol 2004; 11: 241–252
   PubMedGoogle Scholar
• Bernasconi P, Cipelletti B, Passerini L, Granata T, Antozzi C, Mantegazza R, Spreafico R. Similar binding to glutamate receptors by Rasmussen and partial epilepsy patients' sera. Neurology 2002; 59: 1998–2001
   PubMedGoogle Scholar
• Frassoni C, Spreafico R, Franceschetti S, Aurisano N, Bernasconi P, Garbelli R, Antozzi C, Taverna S, Granata T, Mantegazza R. Labeling of rat neurons by anti-GluR3 IgG from patients with Rasmussen encephalitis. Neurology 2001; 57: 324–327
   PubMedGoogle Scholar
• Levite M, Fleidervish IA, Schwarz A, Pelled D, Futerman AH. Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. J Autoimmun 1999; 13: 61–72
   PubMed Web of Science ®Google Scholar
• Whitney KD, McNamara JO. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J Neurosci 2000; 20: 7307–7316
   PubMedGoogle Scholar
• Koustova E, Sei Y, Fossom L, Wei ML, Usherwood PN, Keele NB, Rogawski MA, Basile AS. LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor. J Clin Invest 2001; 107: 737–744
   PubMedGoogle Scholar
• Twyman RE, Gahring LC, Spiess J, Rogers SW. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 1995; 14: 755–762
   PubMed Web of Science ®Google Scholar
• Ganor Y, Gottlieb M, Eilam R, Otmy H, Teichberg VI, Levite M. Immunization with the glutamate receptor derived peptide GluR3B induces neuronal death and reactive gliosis, but confers partial protection from pentylenetetrazole-induced seizures. Exp Neurol 2005; 195: 92–102
   PubMedGoogle Scholar
• Levite M, Hermelin A. Autoimmunity to the glutamate receptor in mice—a model for Rasmussen's encephalitis?. J Autoimmun 1999; 13: 73–82
   PubMedGoogle Scholar
• Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen's encephalitis. Neurology 1996; 46: 242–246
   PubMed Web of Science ®Google Scholar
• Antozzi C, Granata T, Aurisano N, Zardini G, Confalonieri P, Airaghi G, Mantegazza R, Spreafico R. Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis. Neurology 1998; 51: 302–305
   PubMed Web of Science ®Google Scholar
• Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287: 1088–1089
   PubMed Web of Science ®Google Scholar
• Chapman J, Shoenfeld Y. Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome. Ann NY Acad Sci 2002; 966: 415–424
   PubMedGoogle Scholar
• Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M, et al. Comparison of the primary and secondary antiphospholipid syndrome: A European Multicenter Study of 114 patients. Am J Med 1994; 96: 3–9
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027
   PubMed Web of Science ®Google Scholar
• Blank M, Asherson RA, Cervera R, Shoenfeld Y. Antiphospholipid syndrome infectious origin. J Clin Immunol 2004; 24: 12–23
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von Landenberg P, Lev N, Zaech J, Cervera R, Piette JC, Bertolaccini ML, Hughes GR, Youinou P, Meroni PL, Pengo V, Alves JD, Tincani A, Szegedi G, Lakos G, Sturfelt G, Jonsen A, Koike T, Sanmarco M, Ruffatti A, Ulcova-Gallova Z, Praprotnik S, Rozman B, Lorber M, Chapman J, van-Breda-Vriezman PJ, Damoiseaux J. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004; 31: 1344–1348
   PubMed Web of Science ®Google Scholar
• Sneddon IB. Cerebrovascular lesions and livedo reticularis. Br J Dermatol 1965; 77: 180–185
   PubMedGoogle Scholar
• Frances C, Piette JC. The mystery of Sneddon syndrome: Relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun 2000; 15: 139–143
   PubMedGoogle Scholar
• Kalashnikova LA, Nasonov EL, Borisenko VV, Usman VB, Prudnikova LZ, Kovaljov VU, Kushekbaeva AF. Sneddon's syndrome: Cardiac pathology and antiphospholipid antibodies. Clin Exp Rheumatol 1991; 9: 357–361
   PubMedGoogle Scholar
• Zelger B, Sepp N, Stockhammer G, Dosch E, Hilty E, Ofner D, Aichner F, Fritsch PO. Sneddon's syndrome. A long-term follow-up of 21 patients. Arch Dermatol 1993; 129: 437–447
   PubMedGoogle Scholar
• Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia 1989; 30: 389–399
   PubMedGoogle Scholar
• Ganor Y, Goldberg-Stern H, Lerman-Sagie T, Teichberg VI, Levite M. Autoimmune epilepsy: Distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA. Epilepsy Res 2005; 65: 11–22
   PubMed Web of Science ®Google Scholar
• Ganor Y, Freilinger M, Dulac O, Levite M. Monozygotic twins discordant for epilepsy differ in the levels of potentially pathogenic autoantibodies and cytokines. Autoimmunity 2005; 38((2))139–150
   PubMedGoogle Scholar
• Cohen-Kashi K, Ganor Y, Levite M, Teichberg VI. Autoantibodies against an extracellular peptide of the GluR3 subtype of AMPA receptors activate both homomeric and heteromeric AMPA receptor channels (Submitted).
   Google Scholar
• Levite M, Hart IK. Immunotherapy for epilepsy. Expert Rev Neurotherapeutics 2002; 2: 804–819
   Google Scholar
• Yudkoff M, Daikhin Y, Nissim I, Lazarow A. Ketogenic diet, amino acid metabolism, and seizure control. J Neurosci Res 2001; 66: 931–940
   PubMed Web of Science ®Google Scholar
• Abumohor P, Cerda C, Neira O, Palma S, Alvarado MA, Basualdo J, Bravo M, Guzman L. Anticardiolipin antibodies in systemic lupus erythematosus: Prevalence and clinical associations. Rev Med Chil 1991; 119: 517–523
   PubMedGoogle Scholar
• Ghedira I, Sakly W, Jeddi M. Clinical and serological characteristics of systemic lupus erythematosus: 128 cases. Pathol Biol (Paris) 2002; 50: 18–24
   PubMedGoogle Scholar
• Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR. The primary antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore) 1989; 68: 366–374
   PubMed Web of Science ®Google Scholar
• Peltola JT, Haapala A, Isojarvi JI, Auvinen A, Palmio J, Latvala K, Kulmala P, Laine S, Vaarala O, Keranen T. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med 2000; 109: 712–717
   PubMedGoogle Scholar
• Cimaz R, Romeo A, Scarano A, Avcin T, Viri M, Veggiotti P, Gatti A, Lodi M, Catelli L, Panzeri P, Cecchini G, Meroni PL. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia 2002; 43: 52–59
   PubMedGoogle Scholar
• Verrotti A, Greco R, Altobelli E, Latini G, Morgese G, Chiarelli F. Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients. Clin Exp Med 2003; 3: 32–36
   PubMedGoogle Scholar
• Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 568–571
   PubMed Web of Science ®Google Scholar
• Liou HH, Wang CR, Chen CJ, Chen RC, Chuang CY, Chiang IP, Tsai MC. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996; 5: 307–312
   PubMed Web of Science ®Google Scholar
• Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, Chuang CY, Chen CY, Tsai MC. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci 1994; 54: 1119–1125
   PubMed Web of Science ®Google Scholar
• Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8: 127–133
   PubMed Web of Science ®Google Scholar
• Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Investig 1997; 100: 613–619
   PubMed Web of Science ®Google Scholar
• Levite M. Autoimmune Epilepsy. Nat Immunol 2002; 3((6))500
   PubMedGoogle Scholar